Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Audrey Nosbaum

Showing results (81-90 of 111) with videos related to

Pageof 12
Sort By:
Science Immunology|September 8, 2019
Regulatory T cells in skin are uniquely poised to suppress profibrotic immune responsesLokesh A Kalekar, Jarish N Cohen, Nicolas Prevel, et al.
American Journal of Clinical Dermatology|June 18, 2024
Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of ExposureEric L Simpson, Jonathan I Silverberg, Audrey Nosbaum, et al.
American Journal of Clinical Dermatology|August 18, 2021
Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial ProgramEric L Simpson, Jonathan I Silverberg, Audrey Nosbaum, et al.
American Journal of Clinical Dermatology|October 13, 2021
Correction to: Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial ProgramEric L Simpson, Jonathan I Silverberg, Audrey Nosbaum, et al.
Journal of the American Academy of Dermatology|October 17, 2022
Intravenous and subcutaneous immunoglobulins-associated eczematous reactions occur with a broad range of immunoglobulin types: A French national multicenter studyPauline Voland, Camille Barthel, Brahim Azzouz, et al.
BMC Pharmacology & Toxicology|January 15, 2014
Hypersensitivity to oxaliplatin: clinical features and risk factorsMarie Parel, Florence Ranchon, Audrey Nosbaum, et al.
Immunity|November 21, 2015
A Wave of Regulatory T Cells into Neonatal Skin Mediates Tolerance to Commensal MicrobesTiffany C Scharschmidt, Kimberly S Vasquez, Hong-An Truong, et al.
Journal of the American Academy of Dermatology|January 12, 2024
Gene profiling in active dermatitis lesions strengthens the diagnosis of allergic contact dermatitisMarine-Alexia Lefevre, Audrey Nosbaum, Amandine Mosnier, et al.
The Journal of Allergy and Clinical Immunology|July 2, 2022
Epicutaneous allergen immunotherapy induces a profound and selective modulation in skin dendritic-cell subsetsLéo Laoubi, Morgane Lacoffrette, Séverine Valsesia, et al.
The British Journal of Dermatology|April 28, 2022
Longer dupilumab dosing intervals in adult patients with atopic dermatitis: experience from a French multicentre retrospective cohort studyFatma Jendoubi, Jason Shourik, Julien Seneschal, et al.
Pageof 12

Showing results (81-90 of 111) with videos related to

Sort By:
Pageof 12
Science Immunology|September 8, 2019
Regulatory T cells in skin are uniquely poised to suppress profibrotic immune responsesLokesh A Kalekar, Jarish N Cohen, Nicolas Prevel, et al.
American Journal of Clinical Dermatology|June 18, 2024
Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of ExposureEric L Simpson, Jonathan I Silverberg, Audrey Nosbaum, et al.
American Journal of Clinical Dermatology|August 18, 2021
Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial ProgramEric L Simpson, Jonathan I Silverberg, Audrey Nosbaum, et al.
American Journal of Clinical Dermatology|October 13, 2021
Correction to: Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial ProgramEric L Simpson, Jonathan I Silverberg, Audrey Nosbaum, et al.
Journal of the American Academy of Dermatology|October 17, 2022
Intravenous and subcutaneous immunoglobulins-associated eczematous reactions occur with a broad range of immunoglobulin types: A French national multicenter studyPauline Voland, Camille Barthel, Brahim Azzouz, et al.
BMC Pharmacology & Toxicology|January 15, 2014
Hypersensitivity to oxaliplatin: clinical features and risk factorsMarie Parel, Florence Ranchon, Audrey Nosbaum, et al.
Immunity|November 21, 2015
A Wave of Regulatory T Cells into Neonatal Skin Mediates Tolerance to Commensal MicrobesTiffany C Scharschmidt, Kimberly S Vasquez, Hong-An Truong, et al.
Journal of the American Academy of Dermatology|January 12, 2024
Gene profiling in active dermatitis lesions strengthens the diagnosis of allergic contact dermatitisMarine-Alexia Lefevre, Audrey Nosbaum, Amandine Mosnier, et al.
The Journal of Allergy and Clinical Immunology|July 2, 2022
Epicutaneous allergen immunotherapy induces a profound and selective modulation in skin dendritic-cell subsetsLéo Laoubi, Morgane Lacoffrette, Séverine Valsesia, et al.
The British Journal of Dermatology|April 28, 2022
Longer dupilumab dosing intervals in adult patients with atopic dermatitis: experience from a French multicentre retrospective cohort studyFatma Jendoubi, Jason Shourik, Julien Seneschal, et al.
Pageof 12